Tag: US15117K1034

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

(Article 223-16 of General Regulation of the French financial markets authority)

- A word from our sponsors -

HomeTagsUS15117K1034

Innventure to Participate in Upcoming Investor Conferences

Leverage Shares by Themes Launches 2X Long and 2X Short SpaceX ETFs Following Historic SpaceX IPO

Capital Bank Announces the Appointment of Don Busick to Its Board Leadership Team

Tag: US15117K1034

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Monthly information on share capital and company voting rights

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Monthly information on share capital and company voting rights

Explore

Press Releases

News & Opinion

Living

Others

Follow us